Please assess the completion status of the following clinical trial:

Trial Title: The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female aged ≥ 25 years~2. Patient or substitute decision maker willing and able to give informed consent~3. Incident to dialysis defined as within a 12-week window from the first dialysis treatment (1 week prior to, to 11 weeks after). Patients on all forms of dialysis except CRRT (including peritoneal dialysis, home hemodialysis, in-centre intermittent hemodialysis and nocturnal dialysis) will be eligible. Patients returning to dialysis after transplant graft loss will be eligible.~Exclusion Criteria:~1. Past history of allergy to, or intolerance of, escitalopram~2. Known severe hepatic dysfunction~3. Recent history of active bleeding within the past 3 months (e.g. gastrointestinal bleeding requiring hospitalization) or known bleeding disorder~4. Current use of class I anti-arrhythmic medications; SSRI or SNRI antidepressants; pimozide, MAO inhibitors, reserpine, guanethidine, cimetidine or methyldopa, omeprazole; tri-cyclic and tetra-cyclic anti-depressants, neuroleptics or anti-convulsants, triptans, tramadol, linezolid, tryptophan, and St. John's Wort; but not gabapentin~5. Past treatment failure for depression with escitalopram or with ≥ 2 antidepressant treatments of at least 6 weeks duration each~6. Initiation of psychotherapy for depression in the 3 months prior to study entry~7. Alcohol or substance abuse or dependence that requires acute detoxification at study entry~8. Present or past psychosis or bipolar disorder, schizophrenia or any other psychotic disorder documented in medical records~9. Suicidal ideation defined as the patient is at significant risk of suicide on the Columbia Suicide Scale71 or has attempted suicide within 6 months prior to the Screening Visit~10. Clinically-identified major depressive disorder that, in the opinion of the clinical team, requires treatment~11. Pregnancy, lactation and women of childbearing potential not using adequate contraception~12. Abnormal QTc at baseline: QTcF interval \>600 ms (based on the Fredericia correction where QTcF = QT/RR0.33)66~13. Lactose intolerance (as placebo contains lactose)~14. Known uncontrolled glaucoma~15. Patients requiring treatment with continuous renal replacement therapy (CRRT)~16. Documented history of brain tumour

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).